{"date":"2025-12-01","count":18,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6696-2025-12-01-2142-63gdoe","company_id":"6696","company":"仁新*","market":"興櫃","industry":"生技醫療","date":"2025-12-01","time":"21:42:10","subject":"本公司受邀參加富邦證券舉辦之倍利生技投資論壇","clause":"第30款","fact_date":"2025-12-02","cite_as":"公開資訊觀測站重大訊息：仁新*（6696），2025-12-01 21:42，「本公司受邀參加富邦證券舉辦之倍利生技投資論壇」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6696-2025-12-01-2029-o7v1xf","company_id":"6696","company":"仁新*","market":"興櫃","industry":"生技醫療","date":"2025-12-01","time":"20:29:47","subject":"代重要子公司Belite Bio, Inc公告LBS-008針對斯特格病變青少年病患全球第三期臨床試驗之關鍵性數據，主要評估指標之統計結果正面，達到統計上顯著意義","clause":"第44款","fact_date":"2025-12-01","cite_as":"公開資訊觀測站重大訊息：仁新*（6696），2025-12-01 20:29，「代重要子公司Belite Bio, Inc公告LBS-008針對斯特格病變青少年病患全球第三期臨床試驗之關鍵性數據，主要」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6696-2025-12-01-1940-lebi8d","company_id":"6696","company":"仁新*","market":"興櫃","industry":"生技醫療","date":"2025-12-01","time":"19:40:51","subject":"公告本公司召開重大訊息說明記者會","clause":"第44款","fact_date":"2025-12-01","cite_as":"公開資訊觀測站重大訊息：仁新*（6696），2025-12-01 19:40，「公告本公司召開重大訊息說明記者會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6730-2025-12-01-1751-z6rxem","company_id":"6730","company":"常廣","market":"上櫃","industry":"生技醫療","date":"2025-12-01","time":"17:51:51","subject":"公告本公司股票初次上櫃前現金增資發行新股承銷價格","clause":"第44款","fact_date":"2025-12-01","cite_as":"公開資訊觀測站重大訊息：常廣（6730），2025-12-01 17:51，「公告本公司股票初次上櫃前現金增資發行新股承銷價格」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6919-2025-12-01-1723-rj6kph","company_id":"6919","company":"康霈*","market":"上市","industry":"生技醫療","date":"2025-12-01","time":"17:23:07","subject":"本公司114年12月4日受邀參凱基證券舉辦之法人說明會","clause":"第12款","fact_date":"2025-12-04","cite_as":"公開資訊觀測站重大訊息：康霈*（6919），2025-12-01 17:23，「本公司114年12月4日受邀參凱基證券舉辦之法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7832-2025-12-01-1625-7jafwh","company_id":"7832","company":"智新生技*","market":"興櫃","industry":"生技醫療","date":"2025-12-01","time":"16:25:33","subject":"本公司受邀參加富邦證券舉辦之倍利投資論壇","clause":"第30款","fact_date":"2025-12-02","cite_as":"公開資訊觀測站重大訊息：智新生技*（7832），2025-12-01 16:25，「本公司受邀參加富邦證券舉辦之倍利投資論壇」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4127-2025-12-01-1620-19nh5oc","company_id":"4127","company":"天良","market":"上櫃","industry":"生技醫療","date":"2025-12-01","time":"16:20:35","subject":"本公司受邀參加華南永昌證券舉辦之線上法人說明會","clause":"第12款","fact_date":"2025-12-02","cite_as":"公開資訊觀測站重大訊息：天良（4127），2025-12-01 16:20，「本公司受邀參加華南永昌證券舉辦之線上法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6917-2025-12-01-1601-vqv3kq","company_id":"6917","company":"竟天","market":"興櫃","industry":"生技醫療","date":"2025-12-01","time":"16:01:47","subject":"本公司公告APC101正式向美國FDA申請進行第二b/三期臨床試驗","clause":"第8款","fact_date":"2025-12-01","cite_as":"公開資訊觀測站重大訊息：竟天（6917），2025-12-01 16:01，「本公司公告APC101正式向美國FDA申請進行第二b/三期臨床試驗」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6467-2025-12-01-1549-1aq7iqo","company_id":"6467","company":"泰合","market":"興櫃","industry":"生技醫療","date":"2025-12-01","time":"15:49:32","subject":"本公司受邀參加元大證券舉辦之法人說明會","clause":"第30款","fact_date":"2025-12-08","cite_as":"公開資訊觀測站重大訊息：泰合（6467），2025-12-01 15:49，「本公司受邀參加元大證券舉辦之法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1752-2025-12-01-1505-194aq5z","company_id":"1752","company":"南光","market":"上市","industry":"生技醫療","date":"2025-12-01","time":"15:05:39","subject":"本公司受邀參加福邦證券舉辦之法人說明會","clause":"第12款","fact_date":"2025-12-10","cite_as":"公開資訊觀測站重大訊息：南光（1752），2025-12-01 15:05，「本公司受邀參加福邦證券舉辦之法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6892-2025-12-01-1503-1nrvdil","company_id":"6892","company":"台寶生醫","market":"興櫃","industry":"生技醫療","date":"2025-12-01","time":"15:03:39","subject":"公告本公司114年現金增資認股基準日暨相關事宜","clause":"第9款","fact_date":"2025-12-01","cite_as":"公開資訊觀測站重大訊息：台寶生醫（6892），2025-12-01 15:03，「公告本公司114年現金增資認股基準日暨相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6534-2025-12-01-1431-109nn98","company_id":"6534","company":"正瀚-創","market":"上市","industry":"生技醫療","date":"2025-12-01","time":"14:31:33","subject":"公告本公司聘任新任財會處處長","clause":"第8款","fact_date":"2025-12-01","cite_as":"公開資訊觀測站重大訊息：正瀚-創（6534），2025-12-01 14:31，「公告本公司聘任新任財會處處長」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4157-2025-12-01-1417-dco5d7","company_id":"4157","company":"太景*-KY","market":"上櫃","industry":"生技醫療","date":"2025-12-01","time":"14:17:12","subject":"代子公司太景生物科技股份有限公司及太景醫藥研發(北京)有限公司公告與健康元藥業集團股份公司簽署支氣管擴張症新藥TG-4318授權協議","clause":"第10款","fact_date":"2025-12-01","cite_as":"公開資訊觀測站重大訊息：太景*-KY（4157），2025-12-01 14:17，「代子公司太景生物科技股份有限公司及太景醫藥研發(北京)有限公司公告與健康元藥業集團股份公司簽署支氣管擴張症新藥TG-43」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6598-2025-12-01-1414-15yhvdj","company_id":"6598","company":"ABC-KY","market":"上市","industry":"生技醫療","date":"2025-12-01","time":"14:14:30","subject":"公告本公司法人董事改派法人代表人","clause":"第6款","fact_date":"2025-12-01","cite_as":"公開資訊觀測站重大訊息：ABC-KY（6598），2025-12-01 14:14，「公告本公司法人董事改派法人代表人」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6861-2025-12-01-1402-194aq5z","company_id":"6861","company":"睿生光電","market":"上市","industry":"生技醫療","date":"2025-12-01","time":"14:02:28","subject":"本公司受邀參加福邦證券舉辦之法人說明會","clause":"第12款","fact_date":"2025-12-16","cite_as":"公開資訊觀測站重大訊息：睿生光電（6861），2025-12-01 14:02，「本公司受邀參加福邦證券舉辦之法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1795-2025-12-01-1331-sqgrt0","company_id":"1795","company":"美時","market":"上市","industry":"生技醫療","date":"2025-12-01","time":"13:31:58","subject":"公告本公司法人董事代表人異動","clause":"第6款","fact_date":"2025-12-01","cite_as":"公開資訊觀測站重大訊息：美時（1795），2025-12-01 13:31，「公告本公司法人董事代表人異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4905-2025-12-01-1133-1fiirqi","company_id":"4905","company":"台聯電","market":"上櫃","industry":"生技醫療","date":"2025-12-01","time":"11:33:06","subject":"更正本公司114年第三季合併財務報告附註附表二、為他人背書保證","clause":"第53款","fact_date":"2025-12-01","cite_as":"公開資訊觀測站重大訊息：台聯電（4905），2025-12-01 11:33，「更正本公司114年第三季合併財務報告附註附表二、為他人背書保證」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4147-2025-12-01-0628-1few51t","company_id":"4147","company":"中裕","market":"上櫃","industry":"生技醫療","date":"2025-12-01","time":"06:28:52","subject":"中裕新藥與俄羅斯R-Pharm公司簽訂指定患者藥物使用計劃(PA-NPP)供應協議","clause":"第10款","fact_date":"2025-12-01","cite_as":"公開資訊觀測站重大訊息：中裕（4147），2025-12-01 06:28，「中裕新藥與俄羅斯R-Pharm公司簽訂指定患者藥物使用計劃(PA-NPP)供應協議」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}